Joseph W. LaPlume, who serves as Executive Vice President of Corporate Strategy & Development at Charles River Laboratories International Inc (NYSE: CRL), bought 25 shares of the company's common stock on March 3, 2026. The shares were acquired at a per-share price of $174.54, yielding a total transaction value of $4,363. After completing this purchase, LaPlume's direct holdings in Charles River Laboratories total 27,448 shares.
Separately, published analysis on InvestingPro indicates that the stock appears undervalued at current levels. The platform notes the company's $8.84 billion valuation and advertises six additional ProTips and a comprehensive Pro Research Report for users seeking more detailed analysis of the business.
On the corporate performance front, Charles River Laboratories reported fourth-quarter results for 2025 that beat consensus expectations. The company recorded adjusted earnings per share of $2.39, topping estimates by $0.04. Revenue for the quarter was $994.2 million, ahead of the consensus forecast of $987.2 million.
In a strategic shift, the company also announced plans to divest its CDMO and Cell Solutions businesses, together with certain European Discovery Services assets. The CDMO and Cell Solutions businesses generated combined annual revenue of $143 million in 2025. These businesses will be sold to GI Partners, with the deal structure focusing primarily on future contingent performance-based payments.
The divestiture scope includes CDMO sites located in Tennessee, Maryland and the United Kingdom, as well as a Cell Solutions site in California. Management characterized these transactions as part of a broader organizational transformation.
As part of the same organizational changes, Charles River named Glenn G. Coleman to the role of Corporate Executive Vice President and Chief Financial Officer, and appointed Kerry Dailey as Corporate Senior Vice President and Chief Legal Officer. The company described these leadership moves as components of an ongoing transformation within its executive ranks.
Taken together, the insider purchase, the quarter that modestly exceeded expectations, the targeted divestitures and the leadership appointments paint a picture of a company actively reshaping its portfolio and management team. The scope and timing of the divestitures - including specific sites in the U.S. and the U.K. and the sale structure tied to contingent payments - were disclosed by the company as part of its recent announcements.
Readers should note the limits of publicly disclosed information; the filings and company statements cited here provide the details included above, and additional specifics beyond those disclosures were not provided.